Contact Details:

Generics PSAI Proprietary products

North America Active Pharmaceutical Ingredients (API) NCE and Differentiated Products
Dr. Reddy's Laboratories Inc. apiinquiry@drreddys.com Dr. Reddy's Laboratories Inc.
3600 Arco Corporate Drive, Suite 310 200 Somerset Corp. Blvd., Building II,
Charlotte, NC 28273, USA Dr. Reddy's Laboratories Ltd., Floor 7, Bridgewater, NJ 08807
Tel: +1 866 733 3952 Ashoka Hitech Chambers, B-2/120/76/1/B, Tel: +1 908 203 4900
Road No. 2, Banjara Hills, Fax: +1 908 203 4970
Europe Hyderabad 500034, India
Dr. Reddy's Laboratories UK Ltd. Tel: +91 40 664 709 60 Biologics
258 Bath Road, Slough, Fax: +91 40 2355 8941 Dr. Reddy's Laboratories Ltd.
Berkshine, SL14DX, UK Biologics Development Center,
Tel: +44 1753 5125 00 Custom Pharmaceutical Services (CPS) Survey No. 47, Bachupally,
Fax: +44 1753 6966 77 cps@drreddys.com Qutubullapur, R R District 500 123,
Andhra Pradesh, India
India USA
Tel: +91 40 2304 2003/4/5
Dr. Reddy's Laboratories Ltd. Dr. Reddy's Laboratories Inc.
Fax: +91 40 2304 1418
Block-III, Level V, White House, 200 Somerset Corporate Blvd.,
Bridgewater, NJ 08807
Kundanbagh, Begumpet,
Hyderabad 500 016
Tel: +91 40 6602 2500
Tel: +1 908 203 4900
Fax: +1 908 203 4914
PromiusTM Pharma
200 Somerset Corporate Blvd.,
Building II, 7th floor,
Expanding
Fax: +91 40 6602 2595
Europe
Bridgewater, NJ 08807, USA
Tel: +1 908 203 4917
Opportunities
Russia Dr. Reddy's Laboratories (UK) Ltd.
Fax: +1 908 203 4597
Dr. Reddy's Laboratories Ltd. 258 Bath Road, Slough,
bd@promiuspharma.com
Representative Office, 115035, 20, Berkshire, SL1 4DX, UK
Build. 1, Ovchinnikovskaya emb., Tel: +44 1753 5125 00
Business Centre Central City Tower, Fax: +44 1753 6966 77
6th floor, Moscow
Asia Pacific
Tel: +7 495 783 29 01 / +7 495 795 39 39
Dr. Reddy's Laboratories Ltd.
Fax: +7 495 795 39 08
Bollaram Road, Miyapur,
Hyderabad 500 049, India
Tel: +91 40 2304 5737
Global Oncology
Fax: +91 40 2304 6600
Dr. Reddy's Laboratories Ltd.
Survey No. 42, Bachupally, Chirotech Technology Limited, UK
BD/DRL/APR 2009

Qutubullapur Mandal, Unit 162, Cambridge Science Park,

R R District 500 123, AP, India Milton Road, Cambridge CB4 0GH, UK
Tel: +91 40 4434 6200 Tel: +44 1223 728010
Fax: +91 40 4434 6285 chirotechenquiries@drreddys.com

Corporate Development
Dr. Reddy's Laboratories Ltd., Corporate Headquarters, Greenlands, Ameerpet, Hyderabad 500 016, India
Tel: +91 40 2373 1036, Fax: +91 40 2373 1955
businessdevelopment@drreddys.com
 Our products are marketed globally, with a strong focus on India, Russia, Europe and US. Dr. Reddy's
We are committed to conducts NCE research in the areas of metabolic disorders, cardiovascular diseases, anti-infectives

providing affordable and pain/ inflammation.

and innovative Indian Pharma Firsts:

• New York Stock Exchange listing
medicines for • Sarbanes-Oxley (SOX) certification

healthier lives. • 180-days exclusive marketing rights for a

generic drug in the US
• Authorized Generic
• Commencement of Discovery Research
An emerging global pharmaceutical company
• NCE out-licensed for development
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging, fully integrated global
• NCE into Phase III development
pharmaceutical company. We strive to achieve our goals through three core businesses:
• Fastest to reach $1 billion in revenues
• Pharmaceutical Services and Active Ingredients - comprising of our Active Pharmaceutical • HDMA Diana Award winner (2006, 2007 and 2008)
Ingredients and Custom Pharmaceutical Services business • United States Custom and Border Protection Agency certification
• Global Generics - which includes Branded and Unbranded generics

• Proprietary Products - which includes New Chemical Entities (NCEs), Differentiated Formulations, Global Pharma Firsts:
TM
Generic Biopharmaceuticals and a Dermatology focused Speciallty company - Promius Pharma • USP certification under the Pharmaceutical Ingredient Verification Program
• Launch of generic monoclonal antibody
• Polypill (Cardiovascular) Trial

1984:
Dr Anji Reddy
establishes
Dr. Reddy's
Laboratories with an
initial capital outlay
of Rs.25 lakhs

1987:
Obtains its first
USFDA approval for
Ibuprofen API. Starts
its formulations
operations
Driving
value
through
collaboration
Our partnership philosophy is defined by a relationship based on trust and mutual respect. The negotiation, Dr. Reddy's Alliance Management principles and practices facilitate
transaction and alliance process result in a shared vision to create long term value for both partners. successful execution of joint initiatives. While deal execution is

The foundation of our partnership philosophy is based on the following elements: the final stage in the transaction process, we believe that it is

• Diversified business model; multiple product and service offerings only the first step in building a lasting relationship.

• A simple, transparent and streamlined process to progress partnering discussions Following deal execution, an alliance management team is

• Centralized Business Development Council to facilitate thorough diligence of multiple partnership established with the objective of driving collaborative

opportunities and coordination between the different business units programs and championing the interest of both parties

• Flat organizational structure to facilitate swift decision making in the collaboration.

• Effective alliance management processes

• Adherence to highest global regulatory standards

Deal Execution, 1993:

3 Alliance Management Dr. Reddy's Research

The Partnership Process

and Value Realization Foundation established.
The company's drug
discovery programme
starts
Evaluation, Negotiation
2 and Due-Diligence 1997:
Becomes the first Indian
pharmaceutical company
to out-license an original
Preliminary Contact and molecule. First ANDA
1 Opportunity Screening filed with the USFDA for
Ranitidine
Global Unbranded Generics
Generics We have a significant presence in the regulated markets of USA, Germany and UK where we offer high
quality medicines at affordable prices.
Our Branded and Unbranded generic products offer affordable alternatives to innovator brands, both directly
Strengths
and through key partnerships.
• World-class distribution capabilities
• Strong product portfolio and an attractive pipeline
• Proven ability to garner market share
Manufacturing Bandwidth • Credible track record of successful “Day 1” launches
• 7 Formulation plants [6 in India (1 USFDA approved), 1 in US]
• Strong relationships with key distributors, pharmacy chains
Product Portfolio and insurance funds
• Integrated product development center
• 50+ products marketed in the US
Partnering Opportunities
• 130+ ANDAs filed till date. 69 ANDAs pending approval at the USFDA, • In-licensing, co-development and product
of which 32 are Para IV and 19 are FTFs* opportunities in difficult-to-make generics
• 160+ products marketed in the EU • Product portfolio expansion
• 200+ branded formulations marketed in India, Russia and other emerging markets • Partners with unique platform technologies for
• Among the top 10 generic companies in the US; ranks 5th in Germany; the 7th largest product development
Generic Pharma company in Russia and among the largest pharma companies in India

* As on Q3 FY09

2001:
Becomes the first
Asia Pacific
pharma company,
outside Japan, to
list on NYSE

Launches its first

generic product,
Ranitidine, in the
US market
Branded Generics • Working with top 5 distributors
• Coverage of 66 town classes, 50800 doctors, 20000 retailers and 500 hospitals

Our Branded Generics portfolio offers over 200 products in the major therapeutic areas of gastro-intestinal, Partnering Opportunities
cardiovascular, pain management, oncology, anti-infectives, paediatrics and dermatology. Our top brands enjoy • In-licensing opportunities in Differentiated Products and NCEs (phase III, registered, marketed) in

leadership positions in our key markets of India, Russia & the CIS, Romania and Venezuela. gastro-intestinal, cardiovascular, metabolic disorders, pain, anti-infectives and dermatology
• Partnerships to build Hospital and Paediatric portfolio
India • Life cycle management opportunities for big brands
• Among the largest pharmaceutical companies
• Product portfolio of over 200 brands across 13 therapeutic areas
• Market leader in gastro-intestinal, cardiovascular, pain management and oncology
• 2000+ sales and marketing team
• 300,000+ doctors and 1900+ stockist
• Near 100% coverage of KOLs and key institutes
Global Oncology
• Stamlo, Omez, Reditux, Nise, Ketorol are market leaders in their respective category
Strengths
Russia
• One stop portfolio solution with a broad product
• Among the top 15 pharma companies. 14th in retail segment
basket for launches across the globe
• Fastest growing international branded generic company by volumes
• Established capabilities in chemistry and
• Top 5 brands occupy the 1st spot in their respective molecule space
biology enabling strong IP positions
• 4 brands [Omez, Ketorol, Nise and Ciprolet] among Top 100
• Low cost development and manufacturing
• Strong presence in gastro-intestinal, cardiovascular, anti-Infective, oncology, pain and dermatology
operations
• Building capabilities in wellness and nutraceuticals
• Strong commercial infrastructure in focus
• 300 + sales and marketing team
geographies

Partnering opportunities
• Partners for commercialization of our portfolio
• In-licensing opportunities in:
- Differentiated Products and NCEs 2001:
Becomes the first
(phase III, registered, marketed) Indian
- Complimentary basket of oncology products pharmaceutical
company to obtain
• Co-development and joint commercialization of molecules 180-day exclusive
marketing rights for a
generic drug in the US
market with the
launch of Fluoxetine
40 mg capsules on
August 3, 2001
Pharmaceutical Services Active Pharmaceutical
and Active Ingredients Ingredients (API)
The Pharmaceutical Services and Active Ingredients business of Dr. Reddy's serves Generics and Innovator We offer an unparalleled portfolio to our customers, who include innovators and generic formulators
companies through the Active Pharmaceutical Ingredients (API) and Custom Pharmaceutical Services (CPS) worldwide. With more than 150 products, including cytotoxic and hormones,
businesses respectively. and our “first in, last out” approach, we are among the top three
API players globally.

Strengths
• Manufacturing Bandwidth • Broad Global Portfolio: Portfolio of 140+ USDMFs,
- 8 USFDA approved facilities (6 in India, 1 in Mexico and 1 in UK)
80+ EDMFs and several filings in the Rest-of-the-World
- 3 Technology Development Centers (2 in India and 1 in UK)
markets
• Among the top three API players globally • Global Presence: Sales in over 85 countries
• Product Portfolio • Large scale of operations: 8 USFDA approved
- 150+ APIs in the market facilities; serving 300+ SKUs across the globe;
- 20 products under development at any given point of time
unmatched scale-up facilities
• IP leveraged wide basket of assets • Strong product lifecycle management
• Cost effective API pipeline; end-to-end services and competitive pricing • Cost and technology leadership

Partnering Opportunities
• Sourcing opportunities for products globally
• Technology platforms to achieve breakthrough costs for better lifecycle
management
• Partnerships to build capabilities and strengthen the overall value chain

2005:
Acquires Roche's API
Business at the
state-of-the-art
manufacturing site in Mexico
with a total investment of
USD 59 million

2006:
Acquires betapharm- the
fourth-largest generics
company in Germany. The
largest overseas acquisition
ever by an Indian company.
Becomes the fastest Indian
Pharma company to cross $1
billion in revenues
Custom Pharmaceutical
Services (CPS)
Challenge, Lifeline, Value Enabling
The CPS business today is a partner of choice for the strategic outsourcing needs of 'Innovators', both big
pharma and emerging biotech companies worldwide.
Partners will benefit from our years of experience in developing and extending product life cycles and
enhancing intellectual property. Our services and capabilities go beyond the boundaries of contract services and
enable value creation through different stages of pharmaceutical development.
Proprietary
Products
Our Proprietary Products business comprises of New Chemical Entities (NCEs), Generic
Biopharmaceuticals, Differentiated Formulations and a Dermatology focused Specialty company -
PromiusTM Pharma. We are building world-class capabilities and partnerships to accelerate the discovery
and development of new and improved therapies in select diseases.

Strengths: Development and Manufacturing Bandwidth

• Cost effectiveness, speed and flexibility in project execution • cGMP E.Coli and Mammalian cell-culture manufacturing facilities with filling and finishing
• Broad service offerings
• Dedicated product development teams for differentiated products and PromiusTM Pharma
- Process development and scale up to commercial manufacturing of drug substance and drug products
- Customized solutions with a range of products ( APIs and dosage forms)
- Technology leveraged manufacturing services including chiral technology (asymmetric hydrogenation,
hydroformulation and bio catalysis)
- Activated mPEGs/Pegylation
Discovery Research
- Steroidal API manufacturing Strengths
• IP advantaged basket of assets • Discovery and development efforts in metabolic disorders (type 2 diabetes, obesity, dyslipidemia),
anti-bacterials and pain/inflammation
Partnering Opportunities: We offer
• History of successful R&D collaborations with external partners
• Life cycle management solutions
• Creative risk-sharing partnerships that leverage strengths in therapeutic areas of focus
• End-to-End services in development and manufacturing
• Systematic project management principles and processes for timely execution and monitoring of
development programs

Partnering opportunities
2007:
• Co-development and commercialization partners for internal programs. Becomes #1
• In-licensing of drug delivery technology platforms in metabolic disorders, anti-bacterials pharmaceutical
company in India in
and pain/inflammation turnover and
profitability

Launches Reditux™
(rituximab) the
world's first generic
monoclonal antibody
Biologics PromiusTM Pharma
We view generic biopharmaceuticals as an integral part of our mid to long term growth strategy and believe that PromiusTM Pharma is a branded Specialty company with a portfolio of in-licensed dermatology products
building depth in development and manufacturing capabilities will be critical in accessing this opportunity. We have and an internal pipeline in different stages of development. PromiusTM Pharma's current portfolio contains
made significant efforts in this direction and have over the years succeeded in creating world class infrastructure innovative products for the treatment of psoriasis, atopic dermatitis and seborrheic dermatitis.
and a highly capable team.
Strengths
Strengths • 2 products in the market: EpiCeram® Skin Barrier Emulsion and
• Proven generic biopharmaceutical development capabilities with two marketed Scytera® Foam, 7 products in pipeline
products - Grafeel (filgrastim) and Reditux (rituximab), in emerging markets • Track record of successful partnerships with Ceragenix,
• Developed and launched Reditux (rituximab) - the world's first generic monoclonal antibody Foamix, Sinclair and Antares
• Pipeline of eight generic biopharmaceuticals in various stages of development with two • Strong portfolio of in-licensed and co-developed
in clinical development dermatological products and an internal pipeline
• The product portfolio spans multiple therapeutic areas - oncology, auto-immune diseases and CNS under development
• cGMP facilities to manufacture Biologics, in adherence with global regulatory requirements at a significant • Strong and committed sales force
cost advantage • State-of-the-art integrated product development
center in Hyderabad, India
Partnering opportunities
• Partners with intent and capabilities to commercialize generic biopharmaceuticals in specific geographies Partnering opportunities
• Partners developing generic biopharmaceuticals as differentiated product or for new indications and • In-licensing and product opportunities in branded
want to source product dermatology space
• Interested in late stage (phase II, Phase III, ready-to-market, or
in-market) opportunities for development and commercialization
• Out-licensing, co-development and commercialization partners for internal programs for market
outside of the US

2008:
Acquires BASF's
manufacturing facility
at Shreveport,
Louisiana and
Dowpharma's small
molecule business at
its Mirfield and
Cambridge facilities,
UK. Launches its US
Specialty Business,
PromiusTM Pharma,